Filter Results:
(448)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (448)
- Events (2)
- Multimedia (9)
- Faculty Publications (392)
Show Results For
- All HBS Web
(637)
- People (2)
- News (57)
- Research (448)
- Events (2)
- Multimedia (9)
- Faculty Publications (392)
Sort by
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
The $2 trillion health care system is one of the United States' largest industries—but one of its worst performing by almost any measure other than technological innovation. The problems are painful, including escalating costs, expensive insurance premiums, lack of... View Details
- May 1999
- Teaching Note
Genset: 1989 TN
By: Paul A. Gompers
Teaching Note for (9-298-070). View Details
- January 2025
- Case
Moderna: Democratizing Artificial Intelligence
By: Iavor I. Bojinov, Karim R. Lakhani, Annika Hildebrandt and James Weber
The case study examines Moderna's journey in democratizing artificial intelligence (AI), particularly generative AI, across its workforce. It details the company's "digital-first, AI-focused" approach, including the rollout of OpenAI's ChatGPT Enterprise to all... View Details
Keywords: AI and Machine Learning; Technology Adoption; Innovation Strategy; Governance Controls; Biotechnology Industry
Bojinov, Iavor I., Karim R. Lakhani, Annika Hildebrandt, and James Weber. "Moderna: Democratizing Artificial Intelligence." Harvard Business School Case 625-070, January 2025.
- March 2020 (Revised June 2020)
- Case
Social Salary Setting at Spiber
By: Ashley Whillans and John Beshears
Can a “set your own salary” system boost employee happiness and motivation? Spiber made synthetic silk built from proteins mimicking the proteins found in spider silk, the world’s toughest known material by weight. Kazuhide Sekiyama and Junichi Sugahara established... View Details
Keywords: Compensation and Benefits; Motivation and Incentives; Happiness; Negotiation Tactics; Cross-Cultural and Cross-Border Issues; Biotechnology Industry; Japan; United States
Whillans, Ashley, and John Beshears. "Social Salary Setting at Spiber." Harvard Business School Case 920-050, March 2020. (Revised June 2020.)
- September 2019 (Revised August 2020)
- Case
Engineering an Inclusive Bioeconomy
By: Tarun Khanna, Raffaella Sadun and Susie L. Ma
In 2019, entrepreneur Juan Carlos Castilla-Rubio was developing a project he hoped could generate and share wealth from the natural resources of the Amazon without destroying those resources. His idea, called Earth Bank of Codes (EBC), would create a library of the... View Details
Keywords: Decision Making; Development Economics; Entrepreneurship; Innovation and Invention; Intellectual Property; Emerging Markets; Market Design; Marketplace Matching; Science; Genetics; Natural Environment; Environmental Sustainability; Climate Change; Social Enterprise; Strategy; Strategic Planning; Information Technology; Ownership; Social Psychology; Trust; Society; Biotechnology Industry; South America; Amazon Basin
Khanna, Tarun, Raffaella Sadun, and Susie L. Ma. "Engineering an Inclusive Bioeconomy." Harvard Business School Case 720-356, September 2019. (Revised August 2020.)
- November 2017
- Case
Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals
By: Andy Zelleke and Emilie Billaud
This case explores the sustainability efforts at Novozymes, the world's largest and oldest producer of industrial enzymes. In 2015, the Danish company became the world’s first company known to have crafted a new corporate strategy based on the United Nations... View Details
Keywords: Corporate Governance; Transformation; Environmental Sustainability; Corporate Social Responsibility and Impact; Mission and Purpose; Business and Shareholder Relations; Business and Stakeholder Relations; Business Strategy; Organizational Culture; Organizational Change and Adaptation; Biotechnology Industry; Europe; Denmark
Zelleke, Andy, and Emilie Billaud. "Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals." Harvard Business School Case 318-088, November 2017.
- September 2011
- Teaching Note
Tengion: Bringing Regenerative Medicine to Life (TN)
By: Elie Ofek and Natalie Kindred
Teaching Note for 510031. View Details
- September 2009
- Teaching Note
iZumi (TN)
By: Robert F. Higgins
Teaching Note for [809105]. View Details
- December 2004 (Revised July 2005)
- Case
Extend Fertility
By: Myra M. Hart and Sylvia Sensiper
Focuses on the search for opportunity, the generation and evaluation of business concepts, creation of a business plan, and the start-up process. Follows experienced entrepreneur Christy Jones as she combines her business skills and personal experience to generate new... View Details
Keywords: Opportunities; Business Plan; Entrepreneurship; Personal Development and Career; Social Issues; Gender; Business Startups; Biotechnology Industry
Hart, Myra M., and Sylvia Sensiper. "Extend Fertility." Harvard Business School Case 805-065, December 2004. (Revised July 2005.)
- June 2003 (Revised October 2003)
- Case
Institut Pasteur
The Pasteur Institut is implementing a proactive commercialization strategy under the direction of Christian Policard. Highlights the government's innovation policy and the role that the Pasteur Institut can play in shaping it. Also addresses issues relating to higher... View Details
West, Jonathan, Nicolas Mottis, and Mona Ashiya. "Institut Pasteur." Harvard Business School Case 603-069, June 2003. (Revised October 2003.)
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating... View Details
Keywords: Cost Accounting; Financial Reporting; Production; Performance Capacity; Risk and Uncertainty; Genetics; Governing and Advisory Boards; Biotechnology Industry; California
Kaplan, Robert S., and Christina L. Darwall. "Anagene, Inc." Harvard Business School Case 102-030, October 2001. (Revised March 2008.)
- February 1994
- Case
Alpha-Beta Technology, Inc.: Pioneering Carbohydrate Technology
Alpha-Beta was founded in 1988 by two scientist-entrepreneurs with ten patents on carbohydrate technology. In 1991, the company faces critical questions about how to focus its product definition from among several promising, but risky, choices. How should they analyze... View Details
Keywords: Technological Innovation; Product Design; Entrepreneurship; Product Development; Biotechnology Industry
Teisberg, Elizabeth O. "Alpha-Beta Technology, Inc.: Pioneering Carbohydrate Technology." Harvard Business School Case 794-093, February 1994.
- November 1978 (Revised October 1989)
- Case
Amicon Corp. (A)
Amicon holds a patent on a new process for the separation of blood plasma from whole blood. It has to decide whether to pursue a direct entry, joint venture, or licensing strategy. If it chooses licensing, there are many sub-issues to consider. View Details
Capon, Noel. "Amicon Corp. (A)." Harvard Business School Case 579-093, November 1978. (Revised October 1989.)
- October 1987
- Case
T Cell Sciences, Inc.
By: Francis Aguilar
Keywords: Biotechnology Industry
Aguilar, Francis. "T Cell Sciences, Inc." Harvard Business School Case 388-001, October 1987.
- October 2009 (Revised January 2014)
- Teaching Note
Sustainability at Millipore (TN)
Teaching Note for [610012]. View Details
- 12 Sep 2006
- First Look
First Look: September 12, 2006
alliance contracts, all of which concern early-stage research at small, biotechnology R&D companies. Staged investment is ubiquitous, but solutions to agency problems vary. The cycle of equity participation in alliances resembles what... View Details
Keywords: Sean Silverthorne
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
Governmental, academic, and cultural differences are hurting Europe's chances of creating more competitive pharmaceutical and biotech industries—and not much hope is on the horizon, according to a panel of experts at the 2003 HBS European Business Conference. Although... View Details
- June 1990 (Revised April 1993)
- Teaching Note
Novo Industri A/S--1981, Teaching Note
By: W. Carl Kester
Teaching Note for (9-286-084). View Details